CADM3 Antibody

What are the optimal applications and dilutions for CADM3 antibodies?

CADM3 antibodies have been validated for multiple research applications with specific dilution requirements:

It is recommended to titrate the antibody in each specific testing system to obtain optimal results as the ideal dilution may be sample-dependent . For neural tissue applications, antibodies have been successfully validated in mouse brain, rat brain, and human neural tissues .

What are the key specifications for handling CADM3 antibodies?

CADM3 antibodies require specific storage and handling conditions:

• Storage temperature: -20°C, where they remain stable for approximately one year

• Buffer composition: Typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Molecular weight detection: The calculated molecular weight of CADM3 is 43 kDa, but observed weight ranges from 38-50 kDa on Western blots

• Antibody formats: Available as rabbit polyclonal (most common), with specific reactivity to human, mouse, and rat samples

For optimal preservation, avoid repeated freeze-thaw cycles, and consider aliquoting antibodies upon receipt .

How should researchers validate CADM3 antibody specificity?

Robust validation of CADM3 antibody specificity should include:

• Positive controls: Include tissues with known high CADM3 expression (mouse brain, rat brain tissue, and human neural tissues)

• Negative controls: Utilize immunizing peptide blocking experiments where pre-incubation of the antibody with the peptide should abolish specific staining

• Isotype controls: Include appropriate isotype (typically rabbit IgG) to distinguish non-specific binding

• Multiple detection methods: Compare results across Western blot, IHC, and IF to confirm consistent patterns

• Isoform awareness: Note that some antibodies detect only specific CADM3 isoforms. According to available data, at least three isoforms exist, and certain antibodies only detect the two longest isoforms

How can CADM3 antibodies be used to investigate neurological disorders?

CADM3 antibodies provide valuable tools for studying neurological conditions, particularly Charcot-Marie-Tooth disease (CMT):

A specific CADM3 variant (Tyr172Cys) has been identified in patients with axonal Charcot-Marie-Tooth disease (CMT2) . Researchers can employ CADM3 antibodies to:

• Assess protein localization: Compare CADM3 distribution in peripheral nerve samples from patients versus controls using IHC/IF

• Examine subcellular trafficking: Investigate potential retention of mutant CADM3 in the endoplasmic reticulum, as reported in CMT studies

• Study axonal organization: Analyze the distribution of ion channels (Kv1.2) and junction proteins (Caspr) along myelinated axons, which show abnormal patterns in CADM3 mutants

• Co-localization studies: Examine the interaction between CADM3 and CADM4 at intercellular contact sites using super-resolution microscopy such as STORM, which revealed decreased co-localization of mutant CADM3 with CADM4

For comprehensive analysis, researchers should combine antibody approaches with functional assays of nerve conduction and detailed structural examination of myelin.

What methodological approaches can reveal CADM3's role in axon-glia interactions?

To investigate CADM3's function in axon-glia interactions, researchers should implement:

• Co-immunostaining protocols: Combine CADM3 antibodies with markers for:

  • Axonal structures: Neurofilament (NF-H)

  • Paranodal junctions: Caspr

  • Juxtaparanodal regions: Kv1.2

  • Myelinating glia: CADM4

• Genetic model characterization: Utilize antibody-based phenotyping of Cadm3 knockout or point mutation models (e.g., Cadm3Y170C) to assess changes in:

  • Protein expression levels in axons

  • Distribution patterns along myelinated fibers

  • Co-localization with binding partners

• Quantitative analysis: Develop image analysis workflows to measure:

  • Abnormal Caspr immunoreactivity (reported in 70% of sites in Cadm1−/−/Cadm2−/−/Cadm3−/− mice versus 17% in Cadm3−/− single knockouts)

  • Altered Kv1.2 channel distribution along axons

  • Changes in node of Ranvier organization

These approaches can distinguish between the contributions of CADM3 and other family members (CADM1, CADM2) in maintaining proper axonal organization.

How can researchers investigate CADM3's potential tumor suppressor role?

Recent studies suggest CADM3 may function as a tumor suppressor, particularly in breast cancer. Researchers can employ these methodological approaches:

• Expression analysis: Compare CADM3 levels between tumor and adjacent normal tissues using IHC and Western blot. Studies show CADM3 expression is significantly lower in breast cancer tissues compared to adjacent normal tissues

• Correlation with clinical parameters: Analyze CADM3 expression in relation to:

  • Hormone receptor status (ER, PR)

  • Patient age

  • Cancer subtypes (e.g., PAM50 classification)

  • Survival outcomes

• Functional studies: Use cell models with modulated CADM3 expression to assess:

  • Cell proliferation (colony formation, CCK-8 assays)

  • Migration capacity (scratch and transwell assays)

  • Signaling pathway effects (particularly MAPK pathway)

• Mechanistic investigation: Examine CADM3's impact on:

  • MAPK pathway components: Western blot analysis shows ERK1/2 and JNK1 phosphorylation are inhibited in cell lines with high CADM3 expression

  • Immune infiltration: CADM3 expression positively correlates with infiltration of multiple immune cell types, including dendritic cells, T cells, B cells, and NK cells

Immunohistochemistry protocols using CADM3 antibodies have been successfully validated for human breast cancer and colon cancer tissues .

What controls should be included when using CADM3 antibodies in cancer research?

When investigating CADM3 in cancer contexts, researchers should include:

• Tissue controls:

  • Positive control: Normal nervous system tissue with known CADM3 expression

  • Negative control: Tissues with minimal CADM3 expression

  • Matched pairs: Adjacent normal tissue alongside tumor samples from the same patient

• Expression controls:

  • Overexpression systems: Cells transfected with CADM3 expression constructs

  • Knockdown/knockout models: siRNA or CRISPR-modified cells with reduced CADM3 expression

  • Isogenic lines: Cell lines differing only in CADM3 status to control for genetic background

• Technical controls:

  • Secondary-only controls: To assess background staining

  • Competing peptide controls: Pre-absorption with immunizing peptide

  • Correlation with mRNA expression: Validate protein findings with RT-qPCR data

The inclusion of these controls is critical when assessing CADM3's prognostic significance, as high CADM3 expression correlates with better prognosis for breast cancer patients .

How can researchers optimize co-localization studies with CADM3 and interaction partners?

For detailed investigation of CADM3's interactions with binding partners (particularly CADM4), consider these methodological optimizations:

• Sample preparation:

  • Fixation: Use mild fixation conditions (2-4% paraformaldehyde) to preserve membrane protein epitopes and junctional structures

  • Permeabilization: Gentle detergents (0.1-0.3% Triton X-100 or 0.1% saponin) to maintain membrane integrity

  • Blocking: BSA or serum from species unrelated to primary antibodies to reduce non-specific binding

• Antibody selection:

  • Primary antibodies: Choose antibodies raised in different host species to enable simultaneous detection

  • Validated pairs: Select antibody combinations previously demonstrated to work in co-localization studies

  • Epitope consideration: Ensure antibodies target accessible epitopes that won't interfere with protein-protein interactions

• Imaging parameters:

  • Resolution: Use super-resolution techniques (STORM, STED, SIM) to overcome diffraction limits

  • Sequential scanning: Minimize bleed-through between fluorescent channels

  • Z-stack acquisition: Capture the full three-dimensional structure of junctions

  • Quantitative co-localization: Apply appropriate statistical measures (Pearson's correlation, Manders' coefficients)

These approaches have successfully demonstrated decreased co-localization of mutant CADM3 with CADM4 at intercellular contact sites in disease models .

What methodological considerations apply when studying CADM3 in the MAPK pathway context?

When investigating CADM3's relationship with MAPK signaling, researchers should implement:

• Comprehensive pathway analysis:

  • Examine multiple MAPK components: P38, ERK1/2, and JNK, as CADM3 shows differential effects on these proteins

  • Assess both total and phosphorylated forms of signaling proteins

  • Include upstream regulators and downstream effectors

• Experimental design:

  • Time-course experiments: Capture both rapid and sustained signaling changes

  • Dose-dependency: Test varying levels of CADM3 expression

  • Pathway stimulation: Include conditions with growth factors or stress stimuli to activate MAPK signaling

• Validation approaches:

  • Pharmacological inhibitors: Use specific MAPK pathway inhibitors to confirm direct relationships

  • Genetic approaches: Combine CADM3 manipulation with knockdown of MAPK components

  • Rescue experiments: Attempt to reverse CADM3-induced phenotypes through MAPK pathway modulation

Research has shown that ERK1/2 and JNK1 protein phosphorylation is inhibited in breast cancer cell lines (MCF-7 and MDA-MB-231) with high CADM3 expression, suggesting a mechanistic connection between CADM3 and tumor suppression .

How can researchers address weak or non-specific CADM3 antibody staining?

When encountering suboptimal CADM3 staining results, consider these methodological adjustments:

• For weak signal:

  • Increase antibody concentration: Try higher concentrations within recommended ranges (e.g., 1:200 instead of 1:500 for IHC)

  • Extend incubation times: Overnight at 4°C may improve signal compared to shorter incubations

  • Enhance detection systems: Switch to more sensitive detection methods (polymer-based vs. ABC)

  • Optimize antigen retrieval: Test different buffers (citrate, EDTA) and heating methods

• For high background/non-specific staining:

  • Increase blocking time/concentration: Use 5-10% normal serum or BSA for 1-2 hours

  • Add detergent to washes: 0.1-0.3% Tween-20 can reduce non-specific binding

  • Decrease antibody concentration: Dilute primary antibody further

  • Pre-absorb antibody: Incubate with non-specific proteins before application

• For inconsistent results:

  • Standardize fixation: Consistent fixation times and conditions are critical

  • Control tissue processing: Minimize time between collection and fixation

  • Validate with multiple antibodies: Compare results using antibodies targeting different CADM3 epitopes

The observed molecular weight of CADM3 can range from 38-50 kDa on Western blots, so band intensity and specificity should be carefully evaluated against positive controls .

What strategies can improve detection of CADM3 in different experimental systems?

To optimize CADM3 detection across various experimental platforms:

• For Western blotting:

  • Sample preparation: Include protease inhibitors during extraction

  • Loading amount: Start with 20-50 μg of total protein from brain tissue or neural cells

  • Transfer conditions: Optimize for transmembrane proteins (longer transfer times or semi-dry systems)

  • Detection systems: Consider enhanced chemiluminescence for better sensitivity

• For immunohistochemistry:

  • Tissue preparation: Optimal fixation in 4% paraformaldehyde, paraffin embedding

  • Section thickness: 5-10 μm sections provide good resolution

  • Antibody dilutions: Start with 1:50-1:200 for most CADM3 antibodies

  • Visualization systems: DAB-based detection with hematoxylin counterstaining

• For immunofluorescence:

  • Cell fixation: 4% paraformaldehyde for 10-15 minutes

  • Antibody concentration: Begin with 20 μg/mL for primary detection

  • Signal amplification: Consider tyramide signal amplification for weak signals

  • Mounting media: Use media with anti-fade properties to preserve fluorescence

These optimizations have been validated for CADM3 detection in various neural tissues and cell lines, including SH-SY5Y, Jurkat cells, and brain tissue samples .

How might CADM3 antibodies contribute to personalized medicine approaches?

CADM3 antibodies could advance personalized medicine through several investigational avenues:

• Prognostic biomarker development:

  • Patient stratification: High CADM3 expression correlates with better prognosis in breast cancer patients

  • Therapy response prediction: CADM3 status may predict response to specific treatment modalities

  • Recurrence monitoring: Changes in CADM3 expression could indicate disease progression

• Therapeutic target validation:

  • Mechanism exploration: Antibodies can help validate CADM3's role in tumor suppression via MAPK pathway inhibition

  • Companion diagnostics: CADM3 antibody-based assays could identify patients likely to respond to therapies targeting related pathways

  • Treatment resistance mechanisms: Changes in CADM3 expression may contribute to therapy resistance

• Neurological disease applications:

  • CMT subtype identification: Antibodies detecting mutant CADM3 could aid in diagnosing specific forms of Charcot-Marie-Tooth disease

  • Treatment monitoring: Assessing changes in CADM3 localization or expression during experimental therapies

  • Drug development: Screening compounds that restore proper CADM3 localization or function

These approaches could eventually translate laboratory findings into clinical applications for both cancer and neurological disorders.

What are emerging applications of CADM3 antibodies in immunology research?

Recent findings suggest important connections between CADM3 and immune function:

• Tumor microenvironment characterization:

  • CADM3 expression positively correlates with infiltration of multiple immune cell types in breast cancer, including:

    • Dendritic cells (iDC, DC, pDC)

    • T cells (CD8+ T cells, T follicular helper cells, cytotoxic T cells, T effector memory)

    • B cells

    • Natural killer (NK) cells

    • Mast cells

    • Eosinophils

• Mechanistic immunology investigations:

  • CADM3-related genes are functionally associated with:

    • B cell receptor signaling pathway

    • B cell activation

    • Immune receptor activity

    • Mononuclear cell proliferation

    • Lymphocyte proliferation

• Methodological applications:

  • Multi-parameter imaging: Combining CADM3 antibodies with immune cell markers

  • Flow cytometry: Assessing CADM3 expression on immune cells

  • Spatial transcriptomics integration: Correlating CADM3 protein expression with immune signatures

These applications could shed light on CADM3's unexpected roles in immune regulation and potentially inform immunotherapy approaches.